Drug Trial Radar · NCT00286169
Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)
Last checked: Nov 19, 2026Latest source record: Apr 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
130
Planned (sponsor's estimate)
Start
Apr 2006
Primary completion
Not stated
Sponsor
- Lead sponsor
- Sumitomo Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 3, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and toxicity of amrubicin with carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer.
Conditions
- Small-cell Lung Cancer
Interventions
Amrubicin HydrochlorideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Chubu Region Site
Chūbu, Japan
Chugoku Region Site
Chugoku, Japan
Hokkaido Region Site
Hokkaido, Japan
Kanto Region Site
Kanto, Japan
Kinki Region Site
Kinki, Japan
Kyushu Region Site
Kyushu, Japan
Shikoku Region Site
Shikoku, Japan
Tohoku Region Site
Tōhoku, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.